Supplementary Fig. 1. Host expression of CD137 is required for the anti-tumor effects of 2A

A Mice inoculated with EL4E7 tumors on Day 0 and treated with 100µg of either Rat IgG or 2A on Day 7 and Day 10. Statistical significance determined by Log-rank Test: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. Survival and growth curves represent the sum of two experiments. B First panel, CD137 expression on HEK-CD137 transfected cells; second panel, CD137 expression on EL4E7 ex vivo. Gray histogram is the IgG control. C EL4E7 cells incubated with anti-FcγRIIB/FcγRIII, followed with a secondary antibody against Rat IgG. The gray shaded region is secondary antibody only.
Supplemental Fig. 2. Treatment with anti-CD137 mAb does not elicit antibody dependent cellular cytotoxicity (ADCC)

Effector (E) were NK cells isolated from WT and FcγRIII⁻/⁻ mice, Splenocytes were stimulated with ConA for 48 hours to induce CD137. 2A opsonized splenocyte targets (T) were labeled with chromium, and cocultured with the NK cells for 16 hours. Cytotoxicity was determined by the following calculation:

\[
\text{% lysis} = \frac{\text{[experimental cpm - spontaneous cpm] x 100}}{\text{[maximum cpm - spontaneous cpm]}}
\]

YAC-1 is a murine NK sensitive cell line used as a positive control for cytotoxicity.